Oliver Rosen - Sqz Biotechnologies Chief Medical Officer
Insider
Oliver Rosen is Chief Medical Officer of Sqz Biotechnologies Co since 2019.
| Age | 55 |
| Tenure | 6 years |
| Phone | 617 758 8672 |
| Web | https://www.sqzbiotech.com |
Sqz Biotechnologies Management Efficiency
The company has Return on Asset of (0.3332) % which means that on every $100 spent on assets, it lost $0.3332. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.0493) %, meaning that it generated no profit with money invested by stockholders. Sqz Biotechnologies' management efficiency ratios could be used to measure how well Sqz Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities.Sqz Biotechnologies Co has 27.47 M in debt with debt to equity (D/E) ratio of 0.74, which is OK given its current industry classification. Sqz Biotechnologies has a current ratio of 3.79, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Sqz to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Philip Lee | Senti Biosciences | 42 | |
| PharmD Young | Processa Pharmaceuticals | 72 | |
| Inf MD | Candel Therapeutics | 64 | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| MD FACP | AN2 Therapeutics | 77 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
| Joseph Zakrzewski | AN2 Therapeutics | 63 | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| Adrian Ray | Third Harmonic Bio | 48 | |
| Sanjay Chanda | AN2 Therapeutics | 60 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Julie Person | Third Harmonic Bio | 51 | |
| Gregg Keaney | Third Harmonic Bio | N/A | |
| Dan Williams | Inhibikase Therapeutics | N/A | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Chulani Karunatilake | Werewolf Therapeutics | 65 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 63 | |
| Robert Ho | Third Harmonic Bio | 49 | |
| Surendra Singh | Inhibikase Therapeutics | N/A | |
| Francesca MD | Candel Therapeutics | 47 | |
Management Performance
| Return On Equity | -1.05 | |||
| Return On Asset | -0.33 |
Sqz Biotechnologies Leadership Team
Elected by the shareholders, the Sqz Biotechnologies' board of directors comprises two types of representatives: Sqz Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sqz. The board's role is to monitor Sqz Biotechnologies' management team and ensure that shareholders' interests are well served. Sqz Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sqz Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marshelle MD, Chief Officer | ||
| Teri Loxam, Chief Financial Officer | ||
| Howard Bernstein, Chief Scientific Officer | ||
| Marc Schegerin, Independent Director | ||
| Richard CPA, Chief Officer | ||
| Pushkal Garg, Independent Director | ||
| Oliver Rosen, Chief Medical Officer | ||
| Klavs Jensen, Independent Director | ||
| David First, Chief People Officer | ||
| Paul Bolno, Independent Director | ||
| Howard MD, Interim Director | ||
| Armon Sharei, President, Chief Executive Officer, Founder, Interim Chief Financial Officer, Director | ||
| Bernard Coulie, Independent Director | ||
| Amy Schulman, Chairman of the Board | ||
| Marc Elia, Independent Director | ||
| Micah Zajic, Chief Business Officer | ||
| Sapna Srivastava, Independent Director | ||
| Patrick Vink, Independent Director | ||
| Lawrence Knopf, General Counsel | ||
| Ipsita Roymoulik, VP QUALITY |
Sqz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sqz Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.05 | |||
| Return On Asset | -0.33 | |||
| Operating Margin | (3.92) % | |||
| Current Valuation | (6.5 M) | |||
| Shares Outstanding | 29.49 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 66.58 % | |||
| Number Of Shares Shorted | 811.15 K | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 1.24 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Sqz Stock
If you are still planning to invest in Sqz Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sqz Biotechnologies' history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |